Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Genetically Modified Immune Cells Targeting Tumor Antigens Publisher Pubmed



Poorebrahim M1 ; Abazari MF2 ; Sadeghi S3 ; Mahmoudi R4 ; Kheirollahi A5 ; Askari H6 ; Wickstrom SL1 ; Poortahmasebi V7, 8, 9 ; Lundqvist A1 ; Kiessling R1 ; Cidarregui A10
Authors

Source: Pharmacology and Therapeutics Published:2020


Abstract

Immunotherapy approaches consisting of genetically modified immune cells have become a promising platform for cancer treatment. Such ‘living’ therapies targeting tumor antigens have shown success in many cancer patients in the form of durable responses in a growing number of clinical studies. Besides, a large number of ongoing studies have been designed to introduce reliable methods for identification of tumor antigens. In addition, technical and biotechnological developments are being applied to the generation and expansion of genetically modified immune cells. In this review, we summarize and discuss the latest progress and current challenges in the tumor antigen landscape and in the generation of genetically modified immune cells in view of their clinical efficacy, either as monotherapy or combinational therapy. © 2020 Elsevier Inc.
Other Related Docs
5. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
7. Car-Nk Cells for Haematological Cancers, Best Practice and Research: Clinical Haematology (2025)
8. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
16. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)